Saudi Arabia Lung Cancer Therapeutics Market Report 2022 to 2030

Saudi Arabia Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Saudi Arabia Lung Cancer Therapeutics Market will reach a value of $1056 Mn from $507 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as Tabuk Pharmaceuticals, BioVet, and SPIMACO. The Lung Cancer Therapeutics Market in Saudi Arabia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Saudi Arabia lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10SAPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Vishwa Modhia

Buy Now

Saudi Arabia Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Saudi Arabia Lung Cancer Therapeutics market will reach a value of $1056 Mn from $507 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030.

Saudi Arabia is a high-income, developing country in the Middle East bordering the Persian Gulf and the Red Sea. The Saudi Cancer Registry reported 452 instances of lung cancer in 2014, which is a low incidence when compared to international rates. In partnership with the Saudi National Cancer Center, the SLCA has developed a set of guidelines that apply to our patient group, encompassing patient characteristics, disease biology, and practice environment of systemic therapy for lung cancer. All lung cancer patients have access to standard chemotherapy medications such as pemetrexed, taxanes, platinum therapies, gemcitabine, and others.

According to the most recent WHO data published in 2020, 775 people died from lung cancer in Saudi Arabia, accounting for 0.58 % of all deaths. Saudi Arabia ranks 144^th in the world with an age-adjusted death rate of 4.27 per 100,000 inhabitants. Saudi Arabia's government spends 6.2% of its GDP on healthcare in 2020.

Saudi Arabia Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Lung cancer cases accounted for 3.9 % of all cancer cases reported in Saudi Arabia that year, making lung cancer the fourth most prevalent cancer in men and the 17th most common cancer in women. The male-to-female ratio of 3.6:1 reveals a substantial association between smoking prevalence and gender inequalities. Screening for lung cancer in high-risk populations has been shown to lower mortality by 20%, according to the National Lung Cancer Screening Trial. In tertiary hospitals, about 30 qualified consultant thoracic surgeons manage lung cancer. The radiotherapy sector has sparked a great deal of interest in Saudi Arabia, with significant efforts made to keep up with the quickly advancing technological components of radiotherapy. These aspects could boost Saudi Arabia Lung Cancer Therapeutics market.

Market Restraints

The Saudi Lung Cancer Association (SLCA) and Saudi Nationwide Cancer Center guidelines did not suggest mass lung cancer screening as a national programme with required reimbursement. Saudi Arabia's vulnerability in the non-oil economy, combined with COVID-19, heightens the risk to the business. Another issue is the lack of a systematic strategy for lung cancer prevention in primary care. These factors may deter new entrants into the Saudi Arabia Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Tabuk Pharmaceuticals: This Saudi-based company produces a range of oncology drugs, including lung cancer therapeutics
BioVet: This is a Saudi-based biotech company that focuses on the development of novel cancer therapeutics, including those targeted towards lung cancer
SaudiVax: This is a Saudi-based company that specializes in the development and production of vaccines, including those for lung cancer
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): A pharmaceutical company headquartered in Riyadh, Saudi Arabia, with a portfolio of oncology treatments, including for lung cancer

Recent Notable Updates

January 2022: Prime Healthcare, in collaboration with Dubai Healthcare City (DHCC), announced on Tuesday at Arab Health 2022 the establishment of a 100-bed facility that would serve as a Center of Excellence for heart and lung procedures, as well as cancer care. On the second day of Arab Health 2022, the Dubai Healthcare City Authority (DHCA) signed an agreement with Prime Healthcare Group for the historic opening of Prime Heart and Lung Hospital in Dubai Healthcare City Phase 2. Prime Heart and Lung Hospital will be an important addition to the DHCC healthcare enabling ecosystem and will support the mission of the Dubai Healthcare City Authority (DHCA), the governing authority of the Dubai Healthcare City Freezone, to contribute to Dubai's vision of becoming a global health and wellbeing destination.

Healthcare Policies and Reimbursement Scenarios

The Saudi Food and Drug Authority (SFDA) is the regulatory authority in Saudi Arabia in charge of authorising and regulating medicinal pharmaceuticals. In terms of pharmacological treatment, the Saudi Food and Drug Administration licences and promotes new pharmaceuticals, notably in the era of targeted therapy and immunotherapy. Patients are relieved of the significant financial burden of health care because the legislation mandates that all Saudi cancer patients receive free care. Charitable nongovernmental groups help with costs that the government may not cover. These non-profit organisations and societies should be recognised because they play an important role in improving the quality of life of lung cancer patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.